EA202290107A1 - Фармацевтические композиции на основе пептидов, являющихся коагонистами глюкагона и glp-1 - Google Patents

Фармацевтические композиции на основе пептидов, являющихся коагонистами глюкагона и glp-1

Info

Publication number
EA202290107A1
EA202290107A1 EA202290107A EA202290107A EA202290107A1 EA 202290107 A1 EA202290107 A1 EA 202290107A1 EA 202290107 A EA202290107 A EA 202290107A EA 202290107 A EA202290107 A EA 202290107A EA 202290107 A1 EA202290107 A1 EA 202290107A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glp
glucagon
peptides
coagonists
pharmaceutical compositions
Prior art date
Application number
EA202290107A
Other languages
English (en)
Inventor
Ана Люсиа Гомес Дос Сантос
Original Assignee
Медиммун Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиммун Лимитед filed Critical Медиммун Лимитед
Publication of EA202290107A1 publication Critical patent/EA202290107A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение предусматривает составы для парентерального введения пептидов, являющихся агонистами GLP-1/глюкагона, способы получения таких составов и способы лечения с применением таких составов.
EA202290107A 2019-07-01 2020-06-30 Фармацевтические композиции на основе пептидов, являющихся коагонистами глюкагона и glp-1 EA202290107A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962869263P 2019-07-01 2019-07-01
PCT/EP2020/068411 WO2021001374A1 (en) 2019-07-01 2020-06-30 Pharmaceutical compositions for glucagon and glp-1 co-agonist peptides

Publications (1)

Publication Number Publication Date
EA202290107A1 true EA202290107A1 (ru) 2022-03-29

Family

ID=71575348

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202290107A EA202290107A1 (ru) 2019-07-01 2020-06-30 Фармацевтические композиции на основе пептидов, являющихся коагонистами глюкагона и glp-1

Country Status (19)

Country Link
US (1) US20230159606A1 (ru)
EP (1) EP3993823A1 (ru)
JP (1) JP2022539200A (ru)
KR (1) KR20220027204A (ru)
CN (1) CN114126639A (ru)
AR (1) AR119324A1 (ru)
AU (1) AU2020299978A1 (ru)
BR (1) BR112021026575A2 (ru)
CA (1) CA3144177A1 (ru)
CL (1) CL2021003497A1 (ru)
CO (1) CO2021017960A2 (ru)
CR (1) CR20220046A (ru)
EA (1) EA202290107A1 (ru)
IL (1) IL289437A (ru)
MA (1) MA56448A (ru)
MX (1) MX2021015930A (ru)
PE (1) PE20220513A1 (ru)
TW (1) TW202116814A (ru)
WO (1) WO2021001374A1 (ru)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI617574B (zh) 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
JP7237590B6 (ja) * 2016-03-10 2023-03-28 メドイミューン・リミテッド 肥満の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト

Also Published As

Publication number Publication date
US20230159606A1 (en) 2023-05-25
CO2021017960A2 (es) 2022-01-17
PE20220513A1 (es) 2022-04-07
BR112021026575A2 (pt) 2022-04-26
CL2021003497A1 (es) 2022-09-30
CN114126639A (zh) 2022-03-01
WO2021001374A1 (en) 2021-01-07
AR119324A1 (es) 2021-12-09
KR20220027204A (ko) 2022-03-07
IL289437A (en) 2022-02-01
MA56448A (fr) 2022-05-11
CA3144177A1 (en) 2021-01-07
TW202116814A (zh) 2021-05-01
MX2021015930A (es) 2022-02-03
CR20220046A (es) 2022-03-24
AU2020299978A1 (en) 2022-02-24
JP2022539200A (ja) 2022-09-07
EP3993823A1 (en) 2022-05-11

Similar Documents

Publication Publication Date Title
PH12021500014A1 (en) Fused ring compounds
PH12021551065A1 (en) Fused ring compounds
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
PH12020550051A1 (en) Glp-1 compositions and uses thereof
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
EA201891946A1 (ru) Коагонисты глюкагона и glp-1 для лечения ожирения
MA40539A (fr) Procédés de formulation de compositions de conjugués anticorps-médicaments
EA201790254A1 (ru) Новые модуляторы рецептора glp-1
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
JOP20210326A1 (ar) أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
ZA202107825B (en) Pharmaceutical parenteral composition of dual glp1/2 agonist
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
DOP2020000192A (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina y usos de estos
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
PH12020551618A1 (en) Erenumab compositions and uses thereof
EA202290107A1 (ru) Фармацевтические композиции на основе пептидов, являющихся коагонистами глюкагона и glp-1
EA202190217A1 (ru) Формы ивосидениба и фармацевтические композиции
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
CR20220322A (es) Formulaciones de anticuerpos anti-pd-l1
EA202190458A1 (ru) Составы, содержащие дендример
EA202191927A1 (ru) Модуляторы gpr35
EA202191343A1 (ru) Антибиотические соединения, способы их получения, фармацевтические композиции, содержащие их, и их применение